MedMira Advances Rapid Diagnostics With Health Canada Approval
HALIFAX, NOVA SCOTIA | December 30, 2025 — MedMira Inc. reported its first-quarter FY2026 results, highlighting a pivotal period...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
HALIFAX, NOVA SCOTIA | December 30, 2025 — MedMira Inc. reported its first-quarter FY2026 results, highlighting a pivotal period...
SALT LAKE CITY, December 29, 2025 — Co-Diagnostics announced that the Australian Patent Office has granted a key patent...
